Affiliation:
1. The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China
2. Center for General Practice Medicine, Department of Gastroenterology, Zhejiang Provincial People’s Hospital, (Affiliated People’s Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, China
3. Graduate School of Bengbu Medical University, Bengbu, Anhui, China
4. The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou, Zhejiang, China.
Abstract
Background:
Endoscopic treatment is increasingly used for refractory gastroesophageal reflux disease (rGERD). Unlike the mechanism of conventional surgical fundoplication, gastroesophageal junction ligation, anti-reflux mucosal intervention, and radiofrequency ablation have extremely similar anti-reflux mechanisms; hence, we collectively refer to them as endoscopic cardia peripheral tissue scar formation (ECSF). We conducted a systematic review and meta-analysis to assess the safety and efficacy of ECSF in treating rGERD.
Methods:
We performed a comprehensive search of several databases, including PubMed, Embase, Medline, China Knowledge Network, and Wanfang, to ensure a systematic approach for data collection between January 2011 and July 2023. Forest plots were used to summarize and combine the GERD-health-related quality of life (HRQL), gastroesophageal reflux questionnaire score, and DeMeester scores, acid exposure time, lower esophageal sphincter pressure, esophagitis, proton pump inhibitors use, and patient satisfaction.
Results:
This study comprised 37 studies, including 1732 patients. After ECSF, significant improvement in gastroesophageal reflux disease health-related quality of life score (mean difference [MD] = 18.27 95% CI: 14.81–21.74), gastroesophageal reflux questionnaire score (MD = 4.85 95% CI: 3.96–5.75), DeMeester score (MD = 42.34, 95% CI: 31.37–53.30), acid exposure time (MD = 7.98, 95% CI: 6.03–9.92), and lower esophageal sphincter pressure was observed (MD = −5.01, 95% CI: −8.39 to 1.62). The incidence of serious adverse effects after ECSF was 1.1% (95% CI: 0.9%–1.2%), and postoperatively, 67.4% (95% CI: 66.4%–68.2%) of patients could discontinue proton pump inhibitor-like drugs, and the treatment outcome was observed to be satisfactory in over 80% of the patients. Subgroup analyses of the various procedures showed that all 3 types improved several objective or subjective patient indicators.
Conclusions:
Based on the current meta-analysis, we conclude that rGERD can be safely and effectively treated with ECSF as an endoscopic procedure.
Publisher
Ovid Technologies (Wolters Kluwer Health)